Pfizer places its bet on OTC Nexium
August 31 2012
Pfizer is scooping up worldwide marketing rights to the non-prescription version of Nexium for $250 million up front.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.